StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)

Close on Nov 18, 2026Market cap $10.34BP/E –Yield –

Kymera Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Kymera Therapeutics's price to book ratio was 7.4× on Nov 11, 2026, against 5.1× a year earlier. Over the last 5 years it ranged from 1.5× to 7.4×, with a median of 3.7×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20267.4×+1.5
2025Dec 31, 20255.9×+3.0
2024Dec 31, 20242.9×−0.7
2023Dec 29, 20233.6×+0.9
2022Dec 30, 20222.7×−4.1
2021Dec 31, 20216.7×−2.6
2020Dec 31, 20209.4×–

More Kymera Therapeutics figures

See a number that looks wrong?